Generalized Tonic-clonic Seizures
📧 Sign up to get email alerts when something new happens for Generalized Tonic-clonic Seizures.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-26Clinical Trial Update: Cenobamate Open-Label Extension Study for YKP3089C025 [Phase 3]
Open-label extension study for cenobamate (YKP3089) in patients with primary generalized tonic-clonic seizures associated with idiopathic ge…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures [Phase 3]
Phase 3 study to evaluate XEN1101 as adjunctive therapy for primary generalized tonic-clonic seizures is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder [Phase 3]
Phase 3 study evaluating ZX008 for CDKL5 deficiency disorder; current status is ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS withdrawal · 2025-09-15Clinical Trial Update: An Extended Access Program (EAP) for Perampanel
The extended access program for perampanel has ended and is no longer available.
-
FDA approval · 2025-07-11FDA Approved: PERAMPANEL — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original ANDA for PERAMPANEL from Novadoz Pharmaceuticals LLC, making a generic version of perampanel available. This suppo…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures
A clinical trial update describing a study to evaluate the safety of Fycompa Injection (perampanel) in participants with partial-onset seizu…
-
FDA approval · 2025-05-23FDA Approved: PERAMPANEL — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved Teva Pharmaceuticals' original application for a generic version of perampanel. The product is manufactured by Teva Pharmaceuti…
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures [Phase 4]
Phase 4 clinical study evaluating zonisamide as a first add-on therapy for epileptic seizures. The study is currently recruiting at Affiliat…
-
FDA approval · 2025-02-25FDA Approved: LEVETIRACETAM — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for an oral generic formulation of levetiracetam. This approval enables Camber…
-
FDA approval · 2025-02-05FDA Approved: LEVETIRACETAM — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application from BluePoint Laboratories for levetiracetam, authorizing approval of a generic version of the anti…
-
FDA approval · 2024-08-26FDA Approved: LEVETIRACETAM ER — Supplemental Application (Westminster Pharmaceuticals, LLC)
The FDA approved Westminster Pharmaceuticals' supplemental application to authorize the levetiracetam extended-release formulation (LEVETIRA…
-
FDA approval · 2024-07-05FDA Approved: LEVETIRACETAM — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for Levetiracetam from Micro Labs Limited.
-
FDA approval · 2024-04-23FDA Approved: LEVETIRACETAM — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for levetiracetam submitted by Apotex Corp., under ANDA 202958.
-
FDA approval · 2024-01-24FDA Approved: LEVETIRACETAM — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for levetiracetam submitted by NorthStar RxLLC.
-
FDA approval · 2023-10-02FDA Approved: LEVETIRACETAM — Original Application (Baxter Healthcare Corporation)
FDA approved Baxter Healthcare Corporation's original-application generic levetiracetam (ANDA 217059) for seizure disorders, establishing a …
-
FDA approval · 2023-06-13FDA Approved: LEVETIRACETAM — Original Application (Granules Pharmaceuticals Inc.)
FDA approved a generic version of levetiracetam from Granules Pharmaceuticals Inc. under an original ANDA (ANDA217878), expanding access to …
-
FDA approval · 2022-07-15FDA Approved: LEVETIRACETAM — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves Novadoz's original ANDA for Levetiracetam, establishing a generic anti-seizure medication. Indications include epilepsy-related…
-
CLINICAL_TRIALS trial_result · 2022-05-16Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures [Phase 4]
Phase 4 trial evaluating perampanel as monotherapy or first adjunctive therapy for various seizure types in partial onset and generalized se…
-
FDA approval · 2022-03-28FDA Approved: LEVETIRACETAM — Original Application (Solco Healthcare US, LLC)
FDA approves Solco Healthcare US, LLC's generic levetiracetam through an Original Application (ANDA). The approval covers the same epilepsy …
-
FDA approval · 2021-06-11FDA Approved: LEVETIRACETAM — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved the original application (ANDA) for LEVETIRACETAM by ScieGen Pharmaceuticals, authorizing the generic product.
-
FDA approval · 2021-01-19FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for LEVETIRACETAM filed by Prasco Laboratories.
-
FDA approval · 2020-09-30FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA XR (levetiracetam), the extended-release formulation, submitted by UCB, Inc.
-
FDA approval · 2020-06-11FDA Approved: LEVETIRACETAM EXTENDED-RELEASE — Original Application (Omnivium Pharmaceuticals LLC)
FDA approved an extended-release generic formulation of levetiracetam (ANDA212688) manufactured by Omnivium Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2020-04-06Clinical Trial Update: Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures [Phase 3]
Phase 3 trial update for perampanel as adjunctive therapy in pediatric partial onset seizures or primary generalized tonic-clonic seizures; …
-
CLINICAL_TRIALS trial_result · 2020-02-21Clinical Trial Update: A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures [Phase 3]
A Phase 3 study evaluating the safety and tolerability of pregabalin as add-on therapy in pediatric and adult subjects with partial onset se…